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Background: Downregulation of Aldolase B (ALDOB) has been reported in hepatocellular carcinoma. However, its
clinical significance and its role in pathogenesis of HCC remain largely unknown.
Methods: We analyzed the expression of ALDOB and its clinical features in a large cohort of 313 HCC patients using
tissue microarray and immunohistochemistry. Moreover, the function of stably overexpressed ALDOB in HCC cells was
explored in vitro and in vivo. Gene expression microarray analysis was performed on ALDOB-overexpressing SMMC7721
cells to elucidate its mechanism of action.
Results: ALDOB downregulation in HCC was significantly correlated with aggressive characteristics including absence
of encapsulation, increased tumor size (>5 cm) and early recurrence. ALDOB downregulation was indicative of a shorter
recurrence-free survival (RFS) and overall survival (OS) for all HCC patients and early-stage HCC patients (BCLC 0-A and
TNM I stage patients). Multiple analyses revealed that ALDOB downregulation was an independent risk factor of RFS
and OS. Stable expression of ALDOB in HCC cell lines reduced cell migration in vitro and inhibited lung metastasis,
intrahepatic metastasis, and reduced circulating tumor cells in vivo. Mechanistically, we found that cells stably
expressing ALDOB show elevated Ten–Eleven Translocation 1 (TET1) expression. Moreover, ALDOB expressing cells
have higher levels of methylglyoxal than do control cells, which can upregulate TET1 expression.
Conclusion: The downregulation of ALDOB could indicate a poor prognosis for HCC patients, and therefore, ALDOB
might be considered a prognostic biomarker for HCC, especially at the early stage. In addition, ALDOB inhibits the
invasive features of cell lines partly through TET1 expression.Background
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy as well as the second leading cause of cancer-
related deaths worldwide, and its incidence continues to rise
[1, 2]. Although in the past decade, there have been im-
provements in surgical and medical treatments, the out-
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[3, 4]. Cancer classification based on biomarkers may effect-
ively define the risk of recurrence, allowing the use of ap-
propriate treatment for a better prognosis [5]. However,
molecular markers that effectively define the risk of recur-
rence have not been completely explored in patients with
HCC, and the underlying mechanisms responsible for me-
tastasis remain largely unknown [4]. Therefore, more reli-
able biomarkers for predicting relapse and understanding
the mechanisms underlying cancer metastasis need to be
developed urgently [5, 6].
Aldolase B (ALDOB), also known as fructose-
bisphosphate aldolase, is an important enzyme for glucose
and fructose metabolism. It cleaves fructose1-phosphatedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Accumulation of fructose 1-phosphate in tissues due to a
defect in ALDOB may result in hereditary fructose intoler-
ance [7, 8]. Serum levels of ALDOB appear to be a useful
measure of liver cell necrosis in both benign and malig-
nant liver diseases [9]. Results from studies using different
technologies but small sample sizes have shown that both
ALDOB mRNA and protein are dramatically downregu-
lated in HCC as compared to adjacent non-cancerous liver
tissue [10–14]. However, the clinical significance of
ALDOB and its role in the pathogenesis of HCC remain
largely unknown.
In the current study, we found that ALDOB expres-
sion was further reduced in patients with metastasis-
inclined HCC (MIH), in those with primary HCC and
venous metastases (e.g., portal vein tumor thrombus) or
in those with confirmed extrahepatic metastases at follow-
up, compared with metastasis-averse HCC (MAH) and in
those with HCC without detectable metastases. Using
semi-quantitative immunohistochemistry, we explored the
clinico-pathological significance of ALDOB protein in a
cohort of 313 patients with HCC. Downregulation of
ALDOB was associated with multiple malignant character-
istics of HCC. Multiple analyses revealed that the down-
regulation of ALDOB was an independent risk factor for
recurrence-free survival (RFS) and overall survival (OS).Fig. 1 ALDOB were further reduced in metastasis-inclined HCC and in case
and paired non-tumor tissue (NT) in microarray analysis. The HCC cases inc
50 cases of HCC, including 20 MIH and 30 MAH. The expression of ALDOB
Expression of ALDOB mRNA in 25 HCCs with PVTT. The expression of ALDO
IHC stains of ALDOB in matched NT/HCC/PVTTMoreover, ALDOB downregulation was consistently indi-
cative of a shorter RFS and OS in BCLC 0-A and TNM I
stage patients. Furthermore, we generated stable ALDOB
expressing cell lines to explore the role of ALDOB in
HCC. We found that overexpression of ALDOB could in-
hibit cell migration and reduce metastasis in vitro and
in vivo. A gene microarray study on an ALDOB stably ex-
pressing cell line and its control showed that overexpres-
sion of ALDOB induced a high level of Ten–Eleven
Translocation 1 (TET1) expression. We also found that
ALDOB stably expressing cells had a high level of methyl-
glyoxal (MG), which contributes to TET1expression.
Results
ALDOB expression was further reduced in metastasis-
inclined HCC and in cases of portal vein tumor thrombus
Our previously acquired microarray data (GSE54238)
showed downregulation of ALDOB in HCC as compared
to normal liver or paired non-tumor tissue. In this
study, we found that its expression was further reduced
in metastasis-inclined HCC (MIH) as compared to
metastasis-averse HCC (MAH) (Fig. 1a). This indicates
that ALDOB might play a role in development and pro-
gression of HCC. To validate this result, we performed
qRT-PCR analysis of 50 HCC specimens (including 20
MIH and 30 MAH) and paired non-tumor tissues (NT).s of tumor thrombus. a Normalized signal intensities of ALDOB in HCC
luded 14 MIH and 15 MAH. b Relative expression of ALDOB mRNA in
was analyzed by RT-PCR and normalized to β-actin. c The relative
B was analyzed by RT-PCR and normalized to β-actin. d Representative
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cantly downregulated in most HCC tissues (Fig. 1b). In
agreement with the microarray results, ALDOB mRNA
expression was further reduced in MIH (Fig. 1b). Immu-
nohistochemical analysis showed that the protein level of
ALDOB was also downregulated in 68.06 % (196/288) pa-
tients with HCC (Additional file 1: Figure S1A and B).
Portal vein tumor thrombus (PVTT) is the primary route
of metastasis in patients with HCC, and is strongly corre-
lated with poor prognosis. We examined the expression of
ALDOB in 25 cases of PVTT, matched primary tumors
and non-tumor tissues. We found that the levels of
ALDOB mRNA and protein were significantly lower in
cases of PVTT than in primary tumors, as shown in Fig. 1c
and d. These results suggest that ALDOB may play a role
in suppressing HCC metastasis.
ALDOB downregulation is associated with aggressive
clinico-pathological traits
We then performed IHC on the TMA that included
313 HCC specimens to explore the clinical significance
of ALDOB. The expression was recorded by theFig. 2 The downregulation of ALDOB serves as prognostic marker in patien
RFS and a shorter OS than the high ALDOB expression group. The prognos
log-rank test. ALDOB downregulation also indicated worse RFS and OS patevaluation of the staining intensity of the positive cells
(0 = none; 1 = +weak; 2 = ++ intermediate, 3 = +++
strong), as described above. Representative TMA core
staining and scoring is shown in Additional file 1:
Figure S1 C and D. Next, we examined the relationship be-
tween ALDOB expression and the clinico-pathological
characteristics of the 313 patients with HCC (Additional
file 2: Table S1). This analysis revealed that ALDOB down-
regulation was significantly correlated with female gender
(P = 0.016), tumor size >5 cm (P = 0.006), absence of encap-
sulation (P = 0.002) and early recurrence (P = 0.002). The
result also showed that downregulation of ALDOB was
associated with multiple aggressive characteristics of HCC.
ALDOB downregulation serves as a prognostic factor for
patients with HCC
We further sought to determine whether downregulation of
ALDOB was correlated with the prognosis of patients with
HCC after hepatectomy. Kaplan–Meier analysis was used
to compare the subgroups with (n = 145) and without (n =
168) ALDOB downregulation (Fig. 2a and b). Remarkably,
patients showing downregulation of ALDOB expressionts with HCC. a and b The low ALDOB expression group had a shorter
tic significance was assessed by Kaplan–Meier survival estimates and a
ients with in BCLC0-A stage (c and d) or TNM I stage tumors (e and f)
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ively). The 1- and 3 year cumulative recurrence rates were
significantly higher in patients with ALDOB downregula-
tion than in those without ALDOB downregulation (44.3
and 62.0 % versus 28.0 and 42.4 %; P = 0.0031). In addition,
downregulation of ALDOB inversely correlated with 1-and
3 year survival rates (75.9 and 51.7 % versus 87.5 and
70.2 %; P = 0.0023). A univariate analysis revealed that HBs
and HBe antigens, cirrhosis, tumor size, micro-vascular
invasion, macro-vascular invasion, encapsulation, BCLC
stage, TNM stage, and ALDOB expression level were sig-
nificantly correlated with RFS. Additionally, these parame-
ters also correlated significantly with OS (Additional file 2:
Table S2). All significant clinico-pathological parameters
were then used for multiple analyses. A Cox proportional
hazards model showed that ALDOB expression level was
an independent risk factor for RFS (hazard ratio [HR]
1.351, 95 % confidence interval [CI] 1.006–1.815, P = 0.045)
and OS (hazard ratio [HR] 1.437, 95 % confidence inter-
val[CI] 1.030-2.003, P = 0.033) of patients with HCC after
curative hepatectomy (Table 1).
Tumor staging systems based on clinico-pathological
characteristics (e.g., BCLC and TNM staging systems)
can be used to predict outcomes of patients with HCC.
However, correlation between the tumor stage and ac-
tual outcome is not always observed. Some patients with
early stage HCC show poor prognosis, presenting clini-
cians with a major challenge in prognostic prediction for
these patients. We therefore investigated the prognostic
value of ALDOB in early stage HCC. All 313 patients
were stratified according to the BCLC and TNM staging
systems. Kaplan–Meier plots of HCCs of different BCLC
and TNM stages are shown in Fig. 2d-g. Of the 237Table 1 Multivariate analysis of several variables for OS and RFS
Variablea Recurrence-Free Survival
Hazardratio(95 % CI)
HBs antigen, positive 2.046(1.221–3.430)
HBe antigen, positive 1.526(1.093–2.131)
Liver cirrhosis, Present 1.485(1.070–2.061)
Tumor size(cm),>5 1.537(1.143–2.066)
No. tumor, Multiple –
Differentiation, III + IV –
Micro-vascular invasion, Present –
Macro-vascular invasion, Present –
Encapsulation, Absent 1.527(1.113–2.097)
TNM stage, II + III –
BCLC stage, B + C 1.775(1.288–2.444)
ALDOB expression, Low 1.351(1.006–1.815)
N.S., not significant
*P < 0.05 by Cox proportional hazards regression model
aVariables were adopted for their prognostic significance by univariate analysispatients at BCLC0-A stage, 105 had tumors with low ex-
pression levels of ALDOB. Patients with ALDOB down-
regulation had a poorer surgical prognosis and a worse
RFS and OS than the others (37.3 and 57.0 % versus
23.5 and 37.9 % for the 1 and 3 year cumulative recur-
rence rates, respectively; P = 0.0115; 82.9 and 58.1 % ver-
sus 90.2 and 75.0 % for the 1 and 3 year overall survival
rates respectively; P = 0.0114) (Fig. 2c and d). Similarly, of
the 103 patients with TNM I stage HCC, 46 patients with
ALDOB downregulation had a poorer surgical prognosis
as compared to the remaining 57 patients (26.3 and
53.3 % versus14.0 and 26.3 % for the 1 and 3 year cumula-
tive recurrence rates respectively; P = 0.0110; 82.6 and
56.5 % versus 96.5 and 86.0 % for the 1 and 3 year survival
rates respectively; P = 0.0007) (Fig. 2e and f).
Thus, these data indicate that ALDOB could be used
as a prognostic biomarker and a complement for prog-
nostic algorithms (i.e., BCLC and TNM staging systems),
which are based on clinico-pathological characteristics
of patients with HCC.
ALDOB inhibits HCC metastasis in vitro and in vivo
To explore the biological functions of ALDOB in HCC
in vitro, we acquired three HCC cell lines that stably
expressed ALDOB: SMMC-7721, Huh7, and LM6
(named SMMC-ALD, Huh7-ALD, and LM6-ALD, re-
spectively). The expression of ALDOB was validated by
western blot (Additional file 3: Figure S2 C). In the
wound healing migration assay, microscopic examin-
ation at 0 and 48 h showed significant delay in the mi-
gration of SMMC-ALD as compared to the negative
control (Fig. 3a). A Transwell migration assay also
revealed decreased invasiveness in SMMC-ALD cellsOverall Survival













Fig. 3 ALDOB inhibits HCC migration in vitro. The scratch wound healing assays and the Transwell migration assays showed that the overexpression of
ALDOB inhibits the migratory properties of the HCC-derived cell lines SMMC7721 (a and b) and Huh7 (c and d). The representative results and statistical
analysis are shown. Scale bars, 200 μM
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cell lines (Fig. 3c and d, Additional file 4: Figure S3 A-D).
To verify the function of ALDOB in vivo, we injected
SMMC-ALD and Huh7-PGL-ALD cells into the lateral tail
vein of mice to establish a lung metastasis model. Since
Huh7-PGL-ALD and the corresponding control cells
Huh7-PGL-GFP expressed firefly luciferase, the process of
lung metastasis was dynamically monitored every two or
three weeks using an in vivo imaging system. The photon
flux curves indicated that ALDOB expression inhibited
lung metastasis in the lungs (Fig. 4a and b). After 8 weeks,
the lungs were dissected and stained with hematoxylin and
eosin (H&E). We found that lungs from the control
group showed significant and frequent micrometastases
(Fig. 4c and d). Since the SMMC-ALD cells and the corre-
sponding control cells expressed equal levels of greenfluorescent protein (GFP), we detected metastases in lungs
using GFP signals, 8 weeks after injecting the cells.
Weaker signals were observed in lungs of mice injected
with SMMC-ALD, indicating that ALDOB also inhibits
lung metastasis of SMMC7721 cells (Fig. 4e and f).
Furthermore, we injected SMMC-ALD and SMMC-
GFP cells subcutaneously into nude mice. Weekly tumor
volume measurements showed the ALDOB overexpres-
sion group generated less number of tumors (5/8) com-
pares to the controls (8/8) (Additional file 3: Figure S2 F).
We then transplanted tumor tissues into the liver to estab-
lish an orthotopic mouse model. We assessed tumor intra-
hepatic metastases 8 weeks after transplantation and
observed fewer intrahepatic metastases in the SMMC-
ALD group (Fig. 4g and h). As both the control and
ALDOB overexpressing cells were labeled with GFP, we
Fig. 4 (See legend on next page.)
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Fig. 4 ALDOB inhibits HCC metastasisin vivo. a Images of lung metastases that developed in Huh7-pgl4.17 lateral tail vein injection models by the IVIS
Imaging System. Representative luciferase signals captured in each group at the initial injection and 48 days after the injection of the cells are shown.
The statistical analysis is shown in (b). c Representative H&E stained images of lung metastatic loci from each group in A. The statistical analysis is
shown in (d). e Images of lung metastases that developed in SMMC7721 lateral tail vein injection models by the IVIS Imaging System. Representative
GFP signals were captured in each group 49 days after the mice were euthanized. The statistical analysis is shown in (f). g Representative image of
intrahepatic metastases 8 weeks after orthotopic xenograft transplantation of the indicated SMMC7721 cell clones in nude mice. The number of
intrahepatic metastases in each group is shown in (h). i The relative levels of human LINE1 DNA were analyzed by qPCR of genomic DNA from
whole-blood samples 48 days after orthotopic xenograft transplantation of the indicated SMMC-7721 cell clones; expression levels were normalized to
mouse LINE1 DNA. jThe number of GFP-labeled CTCs was examined by flow cytometry from whole-blood samples. The statistical analysis is shown in (k)
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ing tumor cells (CTCs) from whole-blood samples ob-
tained from the orthotopic model. Overexpression of
ALDOB decreased the number of CTCs (Fig. 4j and k).
We validated this result by examining human LINE1
DNA, another indicator of CTCs, in the whole-blood sam-
ples and calculated its ratio to mouse LINE1 DNA to re-
flect the number of CTCs. Consistent with the above
results, mice transplanted with the SMMC-ALD tumors
showed less human LINE1 DNA (Fig. 4i). These data
demonstrate that ALDOB could inhibit intrahepatic me-
tastasis and the spread of the tumor into the circulation
system.
ALDOB inhibits cell migration partly by elevating TET1
expression
To explore the molecular mechanism of ALDOB in the
metastasis of HCC cells, we first examined the effects of
ALDOB overexpression on glycolysis because of its func-
tion in the glycolytic pathway. We measured the expres-
sion levels of other glycolysis genes, in addition to the
amount of glucose and lactic acid, the initial and final
products of glycolysis in the ALDOB-expressing cells.
However, no significant aberrations were detected in the
expression of the tested genes and metabolic products of
glycolysis (Additional file 5: Figure S4 A-C).
We then analyzed the resultant expression profile of
SMMC-ALD cells using a gene microarray platform. Dif-
ferentially expressed genes were then included in func-
tional classification analyses. A total of 167 genes were
significantly upregulated, and 196 genes were downregu-
lated (>2-fold, ALDOB/GFP) (Fig. 5a). GO analyses and
pathway analyses showed that several pathways were
modulated when ALDOB was upregulated (Additional
file 6: Figure S5 A-D).
In addition, we found that expression of TET1, one of
the top ten elevated genes in SMMC-ALD cells, was dra-
matically induced by ALDOB (Fig. 5a). Considering the
role of TET1 in metastasis and cell adherence [15–17], we
first validated its upregulation in cells that stably expressed
ALDOB, as well as its downregulation in ALDOB-
knockdown cells (Fig. 5b and c). We also found the
HOXA9, a known target gene of TET1, upregulated in the
ALDOB expressing cells (Additional file 5: Figure S4 F).Next, we examined the migration potential of SMMC-
ALDOB cells with/without TET1 knockdown using the
Transwell migration assay. We observed that when TET1
was knocked down by siRNA, the inhibitory effects in-
duced by ALDOB were alleviated (Fig. 5d and e). This in-
dicates that ALDOB inhibits metastasis at least partly
through elevation of TET1. Some reports have shown that
ALDOB increases the levels of methylglyoxal (MG) in
endothelial cells [18, 19] and that MG might decrease mi-
gration of HCC cells [20]. In addition, MG can also cause
elevation of TET1 expression in human lens endothelial
cells (HLECs) [21]. Therefore, we examined the concen-
tration of MG in in control cells and cell lines that
expressed ALDOB. Interestingly, we found that MG was
higher in ALDOB-expressing cells than in the control cell
lines (Additional file 5: Figure S4 D). When we added in-
creasing concentrations of MG (0/0.312/0.625/1.25/2.5/
5 mM) to HCC cell lines, we observed notable dose-
dependent upregulation of TET1, as compared to the con-
trols (Additional file 5: Figure S4 E). These data indicate
that the upregulation of TET1 expression by ALDOB
might be mediated through elevation of MG levels.
Discussion
Despite recent improvements in surgical and medical
treatment strategies, prognosis of patients with HCC still
remains unsatisfactory due to frequent recurrence and
metastasis [3, 4]. However, the mechanisms underlying
metastasis remain largely unknown, and the molecular
markers that effectively define the risk of recurrence in
patients with HCC have not been greatly explored.
Therefore, reliable biomarkers are needed to predict re-
lapse and outcome of patients for their optimal medical
management. Moreover, additional biomarkers that play
a role in HCC are needed to explore novel therapeutic
targets.
Increased glycolysis, a hallmark of malignant cancers,
correlates with invasive potential and poor prognosis
[22]. Many glycolysis-related genes are abnormally
expressed in HCC tissues, and some of these genes are
thought to be involved in carcinogenesis of hepatocytes;
moreover, they influence the prognosis of patients with
HCC [23, 24]. ALDOB, an important glycolytic enzyme,
is a well-known specific marker of hepatic differentiation
Fig. 5 (See legend on next page.)
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Fig. 5 ALDOB inhibits cell migration partly though the elevation of TET1. a Differentially expressed genes in SMMC7721-ALDOB cells compared
with control cells. The top 10 up/down-regulated genes are listed on the right. b Relative expression of TET1 in ALDOB stably expressing cells
and paired controls. The expression of TET1 was analyzed by RT-PCR and western blot and was normalized to β-actin. c Relative expression of
TET1 in HepG2 and Huh7 cells with siALDOB and in paired controls. The expression of TET1 was analyzed by RT-PCR and western blot and was
normalized to β-actin. d Transwell migration assays showed that siTET1 could partly relieve the inhibitory effect induced by ALDOB. Scale bars,
200 μM. The statistical analysis is shown in (e)
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ALDOB expression is frequently decreased in liver can-
cer [10–14, 24]. However, its clinical significance and
role in HCC pathogenesis are largely unknown. Our pre-
vious microarray data demonstrated the dramatic down-
regulation of this gene in HCC tissues compared with
paired non-tumor tissues. More interestingly, the ex-
pression of ALDOB is further reduced in MIH. This sug-
gests that ALDOB could be used as a biomarker for
aggressive HCC and that it might be involved in the pro-
gression of HCC.
Hence, in this study, we explored the clinical signifi-
cance and role of ALDOB in HCC pathogenesis. We
measured the ALDOB protein levels in a large cohort of
313 patients and correlated them with the clinico-
pathological features of the patients. ALDOB downregu-
lation correlated with female gender (P = 0.016), tumor
size >5 cm (P = 0.006), absence of encapsulation (P =
0.002) and early recurrence (P = 0.002). A Kaplan–Meier
analysis showed that patients with lower ALDOB expres-
sion had higher recurrence rates (P = 0.0031) and shorter
survival times after curative resection (P = 0.0023).
Moreover, a multivariate analysis revealed that the
ALDOB level was an independent risk factor for both
RFS and OS.
Prognostic algorithms (the BCLC and the TNM sta-
ging systems) based on multiple clinico-pathological
characteristics have better prognostic functions than al-
gorithms based on a single clinico-pathologic factor.
However, even patients with tumors of the same stage
can have different outcomes [27]. Based on the current
staging systems, patients with early stage tumors are
thought to be at a lower risk for recurrence. However,
some of these patients may still show poor prognosis in
clinical practice. Therefore, predicting the prognosis of
these patients is a major challenge for attending clini-
cians. Considering the downregulation of ALDOB in pa-
tients with poor prognosis, we explored its prognostic
value in tumors showing different stages according to
the BCLC and the TNM staging systems. We first strati-
fied all 313 patients according to the BCLC and TNM
staging systems. The patient distribution and 3 year sur-
vival rates in this series were similar to those of previous
reports [28]. Intriguingly, ALDOB downregulation was
consistently indicative of a poor RFS and a poor OS in
patients with BCLC 0-A and TNM I stage tumors. Thus,the findings of the present study suggest that measure-
ment of ALDOB protein levels could identify a worse
prognosis among patients in early stages of HCC. The
prognostic value of ALDOB may be valuable to clini-
cians for distinguishing early stage patients with a high
risk of recurrence. In such cases, close follow-up and ap-
propriate adjuvant therapies should be recommended to
prolong survival.
ALDOB overexpression also inhibited the motility and
metastatic potential of HCC cells both in vitro and in vivo.
In addition, we explored the underlying molecular mech-
anism of action of ALDOB. As no significant aberration
was observed in the expression of glycolysis-related genes
and initial and final metabolic products of glycolysis, we
speculated that ALDOB might not affect glycolysis. This
might due to: First, ALDOA, another enzyme has similar
function, predominantly expressing in cell lines than
ALDOB (Additional file 3: Figure S2 A and B). Second,
ALDOB has a 10 fold lower Km for glyceraldehyde
3-phosphate (G3P) and dihydroxyacetone phosphate
(DHAP) than ALDOA [29], which means ALDOB having
the less ability of conversion fructose-1,6-bisphosphate
F-1,6-BP to G3P and DHAP in glycolysis. Third, the ALDs
are not the key enzyme in controlling glycolysis rate. It is
reported that ALDOA knocking down does not affect the
glycolytic flux and intracellular ATP concentration [30].
However, we found that the MG level was elevated in
ALDOB-expressing cells, which is primarily generated
from G3P and DHAP through non-enzymatic fragmen-
tation of triosephosphates [31]. This might rely on the
ability of ALDOB in cleaving the fructose-1-phosphate
(F-1-P) into G3P and DHAP [32], and this might be the
reason why is ALDOB but not ALDOA affect the MG
level in endothelial cells [18, 19]. We validated the rela-
tionship of MG level and ALDOB expression in HCC
cells. However, the influences of ALDOB in metabolism
still need further exploration. MG has been reported to in-
hibit cell growth in several types of tumors. In HCC cell
lines, MG is thought to influence cell adhesion and inhibit
cell migration. However, since it is difficult to eliminate
MG, whether ALDOB inhibits tumor migration mainly
through MG is still unclear.
We therefore analyzed the resultant expression profile
upon ALDOB overexpression. We observed that in-
creased levels of ALDOB elevated the expression levels
of TET1. TET1 belongs to the ten-eleven translocation
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lyzing 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC), and to a lesser extent, 5-formylcytosine or 5-
carboxylcytosine [33]. TET1 is suppressed in several solid
tumors including HCC and is thought to influence cell ad-
hesion and inhibit cell growth and metastasis [15–17]. In
this study, we observed that ALDOB promotes TET1 ex-
pression. Knock down of TET1 by siRNA promoted HCC
migration and reversed the inhibition of metastasis induced
by ALDOB. All of these results suggest that ALDOB in-
hibits cell metastasis, partly through its regulation of TET1.
Moreover, some reports have shown that addition of MG
to cultures can elevate TET1 expression in lens epithelial
cells [21]. We validated this observation by adding MG to
HCC cells. This experiment indicated that elevation of
TET1 by ALDOB might occur at least partly through MG.
However, as described above, since we lack the means to
eliminate MG under experimental conditions, the relation-
ship between ALDOB/MG/TET1is still unclear and re-
quires further investigation.
In conclusion, this study investigated the expression of
ALDOB and its value as a prognostic biomarker in
HCC. It also explored the biological function of ALDOB
in HCC. We observed that the downregulation of
ALDOB is a predictor of high-risk metastasis and recur-
rence in HCC patients. These patients should be closely
monitored and should receive appropriate adjuvant ther-
apies for a better prognosis. We also found that ALDOB
inhibits HCC metastasis by elevating TET1, a process
that may involve MG. However, the detailed mechanism
of this process is yet to be elucidated.
Materials and methods
Patients and specimens
The study protocol was approved by the clinical research
ethics committee of the Eastern Hepatobiliary Surgery
Hospital. Written informed consent was obtained from
all patients according to the policies of the committee.
Any information that could identify the patients was not
included in this article.
This study included 29 HCC tissues and paired non-
tumorous tissues (including 14 MIH and 15 MAH) for
microarray analysis. Another 50 HCC specimens (including
20 MIH with and 30 MAH) were used for the validation of
microarray data by qRT-PCR analysis. The MIH and MAH
status was defined as described previously [34, 35]. The
MIH group was composed of patients with solitary HCC
that was accompanied either by portal vein metastasis or by
venous metastases at follow-up, or those who had two nod-
ules present at the time of sample collection. The MAH
group was restricted to only those patients with solitary
HCC and no recurrence at follow-up. Samples from 25 pa-
tients with HCC and portal vein tumor thrombosis (PVTT)
were used to test the expression level of ALDOB in pairedHCC/non-tumor tissues/PVTT by qRT-PCR and IHC.
Another 288 HCC cases and paired non-tumor tissues
were used to validate ALDOB protein level by IHC. More-
over, a large HCC cohort of 313 patients with HCC
(randomly collected from January 2006 to September
2010) who received a high-quality follow-up, were used to
examine ALDOB protein levels and the clinical signifi-
cance of ALDOB by tissue microarray (TMA) and IHC.
Normal liver tissues were collected from patients who
underwent resection of hepatic hemangiomas. All liver
specimens were randomly selected from patients who
underwent curative hepatectomy, and all specimens were
pathologically confirmed at the Eastern Hepatobiliary Sur-
gery Hospital between 2005 and 2010 [36].
The preoperative diagnosis was obtained as described
previously, and surgical procedures were performed on
the patients with HCC as described previously [37]. The
clinical characteristics of the HCC cohort are listed in
Additional file 2: Table S1. The differentiation of HCC
was defined according to the criteria proposed by
Edmondson and Steiner (I, well-differentiated; II, moder-
ately differentiated; III, poorly differentiated; IV, undiffer-
entiated). Micro-metastases were defined as tumors that
were located adjacent to the border of the primary
tumor and that could only be observed under the micro-
scope. Tumor staging was conducted according to the
BCLC staging system and the sixth edition of the
Tumor-Node-Metastasis (TNM) classification system
published by the International Union Against Cancer.
All HCC specimens were obtained immediately after
hepatectomy. Tissues were then fixed in 10 % buffered
formalin and embedded in paraffin. Fresh specimens
used in this study were snap-frozen from tissues prior to
formalin fixation and were then transferred to liquid ni-
trogen and stored at −80 °C until use.
Follow-up
All patients with HCC received check-ups every 2–
3 months during the first 2 years and every 3–6 months
there after until the follow-up period ended in January
2013. Physicians who were blinded to the study per-
formed the follow-up examinations. Serum AFP levels
and abdominal ultrasound examinations were performed
every month during the first year after surgery and every
3–6 months thereafter. Computed tomography and/or
magnetic resonance imaging were performed every 3–
6 months or when a recurrence was suspected. A diag-
nosis of recurrence was based on preoperative diagnosis
criteria. Once recurrence was confirmed, further treat-
ment was implemented based on the tumor diameter,
the number of tumors, the location of the tumor, and
the extent of vessel invasion as well as liver function and
performance statuses. The recurrence-free survival (RFS)
was calculated from the date of tumor resection until
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other than HCC, or the last follow-up visit. The overall
survival (OS) was defined as the length of time between
surgery and either the death of the patient or the last
follow-up visit.
Cell lines
The SMMC7721, LM3, LM6, HepG2, Huh7, and Hep3B
cells were obtained from the Chinese Academy of Sciences
Cell Bank and were authenticated by the providers by
DNA-Fingerprinting analysis or isoenzyme analysis. All
cell lines were used at early passages and no morpho-
logical changes or altered growth rates were observed dur-
ing maintenance of the cultures. Cells were grown in
Dulbecco’s modified Eagle’s medium with 10 % fetal bo-
vine serum (Gibco BRL). Cells were maintained in an at-
mosphere of 5 % CO2 in a humidified 37 °C incubator.
Extraction of RNA, Preparation of cDNA and Quantitative
real-time PCR (qRT-PCR)
Total RNA was extracted from snap-frozen tissues with
Trizol reagent (Takara, Dalian, China) according to the
manufacturer’s instructions. The quality of the total
RNA was assessed by a Nanodrop 2000 and agarose gel
electrophoresis. First-strand cDNA was synthesized from
1–2 μg of total RNA using random primers and M-MLV
Reverse Transcriptase (Invitrogen, CA). Real-time PCR
was performed according to the Taqman probe assay
protocol or the SYBR Green protocol in a StepOne Plus
system (Applied Biosystems, Foster City, CA) with β-
actin as the endogenous control. The relative mRNA
levels were calculated based on the Ct values and were
according to the β-actin expression. The primer and
probe sequences are listed in Additional file 2: Table S3.
Western blot analysis
Total protein was extracted from snap-frozen tissues
with RIPA Lysis Buffer and PMSF (Beyotime Co., China)
according to the manufacturer’s instructions. Western
blotting was performed as described previously [38].
Antibody dilutions were 1:1500 for the ALDOB poly-
clonal antibody (Proteintech Group, Inc., Chicago, USA)
and 1:5000 for β-actin (Sigma-Aldrich, USA). Antibody
binding was detected with an Odyssey infrared scanner
(Li-Cor Biosciences Inc).
Tissue microarray construction and immunohistochemical
analysis
The tissue microarray (TMA) was constructed as de-
scribed previously [39]. Briefly, all samples from patients
in the HCC cohort were reviewed histologically by
hematoxylin and eosin staining. Representative areas
were premarked on the paraffin blocks, away from nec-
rotic and hemorrhagic tissue. Two 1.0-mmcores wereextracted from each tumor, were paired with non-tumor
tissue and were mounted on a new recipient block with
a semi-automated arraying device (TMArrayer, Path-
ology Devices, Westminster, MD, USA).
Immunohistochemistry was performed on the TMA with
a two-step immunoperoxidase technique [40]. The ALDOB
polyclonal antibody (Proteintech Group, Inc, Chicago,
USA) diluted 1:60 was used as the primary antibody.
Briefly, after heating the sections in 10 mmol/L citrate buf-
fer for antigen retrieval, the sections were incubated first
with the primary antibody and then with the secondary
antibody for an hour at room temperature. Finally, the sec-
tions were developed in diaminobenzidine solution under a
microscope and counter-stained with hematoxylin.
The immunohistochemical stains were assessed by
three separate observers who had no knowledge of pa-
tient characteristics. ALDOB staining was abundant in
the cytoplasm and nucleus, which was similar to previ-
ous studies [41, 42]. The expression was recorded after
an evaluation of the staining intensity of positive cells (0 =
none; 1 = +weak; 2 = ++ intermediate, 3 = +++ strong).
Scoring differences were discussed until a consensus was
reached. A low level of ALDOB in the HCC specimens
was defined as staining intensity that was designated as ei-
ther “none” or “weak.”
Wound healing migration assay
Wound healing migration assays were performed as de-
scribed previously [38]. Briefly, 1 × 105 cells were plated
in each well of 6-well plates. Once cells were attached,
they were scraped to form a wound in the middle of the
plates and the medium was replaced with serum-free
medium. We measured the area of healing across the
line after an incubation of 36 h.
Transwell assays
Millicell 24-well culture insert plates (Millipore, USA) and
polycarbonate membranes with a pore size of 8 μm were
used in Transwell assays as described previously [38].
First, The insert plates were equilibrated with 0.5 ml of
DMEM for1 h at 37 °C in 5 % CO2, which was then re-
placed with 0.5 ml of DMEM supplemented with 10 %
FBS in the lower chambers. In all, 50,000 cells in 400 μl of
serum-free DMEM were loaded into the upper chambers.
After 24 h of incubation, the insert plates were rinsed with
PBS and the upper surfaces of the membranes were
scraped toremove the cells. The cells on the underside of
the membrane were stained with Giemsa stain and
counted under a microscope. Cells from each culture con-
dition were examined in quadruplicate.
Animal studies
The animal studies were approved by the Institutional
Animal Care and Use Committee of the Second Military
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effects of ALDOB on tumor growth in vivo, 1 ×
107SMMC7721 cells thatstablyexpressedALDOB (SMMC-
ALDOB) and control cells (SMMC-GFP) were subcutane-
ously implanted into the bilateral armpit of nine BALB/C
nude mice. The tumor volume was measured every
week after implantation (the volume V = length × width ×
length × 1/2). All mice were sacrificed five weeks later, and
sections of tumor tissues were transplanted to establish an
orthotopic model as described previously [37, 43]. A tail
vein injection model was also used to evaluate the poten-
tial of the cells to metastasize to the lungs. The metastases
were monitored by the IVIS@ Lumina II system (Caliper
Life Sciences, Hopkinton, MA) for 10 min after intraperi-
toneal injection of 4.0 mg of luciferin (Gold Biotech) in
50 μl of saline.
Statistical analysis
All statistical analyses were performed with SPSS version
18.0 software. The χ2 test or Fisher’s exact test were used
to compare qualitative variables, and the Student’s t-test
or the Mann–Whitney test were used to compare con-
tinuous variables. Survival curves were calculated accord-
ing to the Kaplan–Meier method and were compared by a
log-rank test. A Cox proportional hazards model was used
to determine the independent factors of survival and re-
currence based on variables selected after the univariate
analysis. A difference was defined as significant at P < 0.05.
Additional files
Additional file 1: Figure S1. (A) Average expression level of ALDOB in
HCC and paired non-tumor tissue by IHC; representative IHC stains of
ALDOB areillustrated in (B). (C) Immunohistochemistry score distribution
of the tumors of the 313 patients with HCC. (D) Representative images of
the immunohistochemistry score of ALDOB. (TIFF 5836 kb)
Additional file 2: Table S1-S3. Clinical characteristics of 313 HCC
patients according to ALDOB expression. Table S2. Univariate analysis of
outcomes of 314 patients with HCC. Table S3. The list of primers and
siRNA sequences used in study. (DOCX 19 kb)
Additional file 3: Figure S2. (A) Exact copy number of ALDOB mRNA
in 1 ng RNA from HCC cell lines (upper). The ALDOB protein level in HCC
cell lines by western blot (lower). (B) Exact copy number of ALDOA
mRNA in 1 ng RNA from HCC cell lines (upper). The ALDOA protein level
in HCC cell lines by western blot (lower). (C) The ALDOB protein level in
ALDOB stably expressing cell lines and in paired controls as measured by
western blot. (D) The relative expression of ALODA in ALDOB expressing
cell lines compares to controls. The expression levels of the genes were
analyzed by RT-PCR and normalized to β-actin. (TIFF 10926 kb)
Additional file 4: Figure S3. The scratch wound healing assays and
Transwell migration assays showed that the overexpression of ALDOB inhibits
cell migratory properties in the HCC cell line LM6 (A-D). The representative
results and statistical analysis are shown. Scale bars, 200 μM. (E) The growth
curves of SMMC-ALD and its controls in CCK8 assay. (F) Images of the tumors
that developed in the mouse models after subcutaneous injection of SMMC-
ALDOB and SMMC-GFP cells. (TIFF 6500 kb)
Additional file 5: Figure S4. (A) Relative expression of glycolysis genes
in SMMC-ALDOB and SMMC-GFP cells. The expression levels of the genes
were analyzed by RT-PCR and normalized to β-actin. (B) The relativeglucose concentration in SMMC-ALDOB and Huh7-ALDOB cells normalized to
that in paired controls under the same conditions. (C) The production of lactic
acid in SMMC-ALDOB and Huh7-ALDOB cells as measured by a lactic acid
detection kit (Jian Cheng, NanJing, China) according to the manufacturer’s
instructions. (D) The production of methylglyoxal in ALDOB stably expressing
cells was measured by a methylglyoxal detection kit (JianCheng, NanJing,
China; also TSZELISA, Lexington, USA) according to the manufacturer’s
instructions after 1:105 dilution. (E) The expression of TET1 in cells cultured in
elevated concentrations of MG (0/0.312/0.625/1.25/2.5/5 mM). The expression
was analyzed by RT-PCR and was normalized to β-actin. (F) The expression of
HOXA9 in ALDOB stably expressing cells and in paired controls. The expression
was analyzed by RT-PCR and was normalized to β-actin. (TIFF 2168 kb)
Additional file 6: Figure S5. (A&B) The GO biological process analysis of
up-regulated genes (A) and down-regulated genes (B) in SMMC-ALDOB cells
compared with controls. (C&D) The Parthway analysis of up-regulated genes
(C) and down-regulated genes (D) in SMMC-ALDOB cells compared with
controls. (TIFF 670 kb)
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